Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Alberta and Ontario say they'll renew their efforts to negotiate a reasonable price for a costly drug after a 12-year-old girl pleaded for the government to fund the life-saving treatment.

Madi Vanstone, from Beeton, Ont., has been taking the drug Kalydeco to treat a rare form of cystic fibrosis, a genetic disease that creates a sticky, thick mucus which builds up in the lungs and affects other organs.

But the cost of the pills — $349,000 a year — isn't covered in Ontario, leaving her family and friends to raise the money to pay for the drug.

Story continues below advertisement

Since she started taking the drug, she can play with her friends outside and climb the stairs without struggling for breath, Madi said.

"I didn't have any energy, I had headaches all the time, bellyaches," she said. "And now, that's just gone."

Her 15-year-old sister Jessica said Madi missed months of school last year. But since she's been taking Kalydeco, she hasn't missed a day. She's even taken up sports like running.

"If I go off it, I don't know what I'll do because this improves my life significantly," Madi said.

Ontario Premier Kathleen Wynne, who met with Madi and her mother, said the drug isn't covered yet because the price is still under negotiation.

Some provinces have banded together to use their collective buying power to cut drug costs.

Alberta, which is leading the talks on Kalydeco, has made three proposals to the drug maker Vertex, but it has rejected each one, Wynne said.

Story continues below advertisement

It's not responsible for Ontario to undermine other provinces, she added.

"Of course we don't put a price on a human being's life," she told the legislature.

But a former health minister called her response "complete garbage."

The governing Liberals could fund the drug tomorrow if they wanted to, said Progressive Conservative Jim Wilson. But they have little money left after spending scandals over cancelled gas plants, electronic health records and the province's air ambulance service.

"Obviously the premier believes the price is more important than the quality of life for a 12-year-old girl and others who need the drug," he said.

Alberta's Conservative government says it will keep putting pressure on the manufacturer to reach an agreement.

Story continues below advertisement

There are about 118 Canadians who would be eligible for the drug, including 21 in Alberta, said the province's Health Minister Fred Horne.

But Vertex hasn't offered coverage of their drug under their compassionate care program that drug companies usually offer, he said.

"This is a very frustrating situation," Horne said.

"Vertex needs to come to the table and offer Canadians a fair price for this drug so we can make it available."

But Madi's mother, Beth Vanstone, said she can't understand why it's taking so long — 14 months and counting.

"There are people who are getting sicker and sicker," she said. "The wheels have been spinning and we're not going anywhere."

Story continues below advertisement

The price of Kalydeco has been set in 11 other countries, including Germany, where it costs $450,000 a year, she said.

Both Madi and her mother left the meeting with Wynne and Ontario Health Minister Deb Matthews without the answers they were looking for.

"It was a little bit of spin," Vanstone said.

They weren't able to give her a timeline for when the province might cover the drug, she said.

"I said, I hope we don't have another 14 months of this, and she said, well no, we're going to be working towards it and we can't pay that price," Vanstone said.

"I said, basically you're putting a price on lives."

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies